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Abstract 
BioInnovate Ireland is a specialist training program in medical device innovation and product 
design.  It is modelled on the Biodesign Fellowship programme which has been offered at 
Stanford University, Palo Alto, California since 2001.  
The objective of BioInnovate Ireland is the training of students in a systematic approach to 
needs finding as well as invention and implementation of new biomedical technologies.  This 
thesis explores the methods and processes utilised by the BioInnovate Ireland Dublin team in 
the first year of the programme as they identified a number of unmet clinical needs and 
developed concepts for these needs.  One project which I personally championed and which 
was brought forward to the concept development stage is discussed in detail.  The project 
activity decision with regard to the viability of bringing the project forward to business plan 
is analysed and the lessons which can be learned from the process are also discussed.  
This thesis offers a personal perspective and reflection on the BioInnovate process and the 
potential that it holds for the innovation process within the Irish medical device industry.  
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1.1  Introduction 
The aim of this chapter is to provide a background to the BioInnovate Ireland Fellowship and 
an outline of the various stages it involves. 
1.2 The Medical Device Sector in Ireland  
The medical device sector is of great importance to the Irish economy. Successive Irish 
Governments have attempted to promote Ireland as a location for foreign direct investment 
(FDI).  This has included a heavy focus on the medical device sector.  
IDA Ireland has made Ireland the location of choice for international life science and 
healthcare companies.  Attracting FDI and the establishment of R&D facilities has required 
the provision of manufacturing and operations facilities, retention of attractive taxation rates 
and provision of a highly educated and skilled workforce.  
Apart from the attraction of multi-national medical device companies, there have also been a 
number of successes in the generation of indigenous spin-out and start-up companies 
operating within the Irish medical device sector.  In this way, Ireland has developed a strong 
reputation as a leading medical device industrial cluster. 
Examples of this include the fact that:  
 The global leader in the drug – eluting coronary stent market was researched, 
developed and commercialised in Ireland.  (Irish Venture Capital Association). 
 30 Million People (25% of world’s population) who have diabetes rely on an 
injectable device made in Ireland.  (Irish Medical Devices Association Yearbook - 
Driving Innovation through Collaboration – 2011).  
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 Ireland exported medical technologies worth 7.2 billion in 2010 – up 14% on 2008. 
(IMDA Website). 
 Ireland is the second largest exporter of medical products in Europe.  (Enterprise 
Europe Network – Medical Devices Sector in Ireland 2010) 
1.3 The decision to establish the BioInnovate Ireland Programme  
Forfas is Ireland’s policy advisory board for enterprise and science.  In a 2010 report, it 
underlined the belief that research development and innovation initiatives will be key drivers 
for future growth of the Irish economy.  
Another key impetus for BioInnovate was the report of the Innovation Taskforce which was 
also published in 2010.  The report outlined the importance that innovation holds for Ireland. 
The stated aim of the taskforce was to ensure that by 2020, Ireland would become home for a 
number of world-leading innovation-intensive companies and that these companies would be 
either Irish-owned or be headquartered here.  This was thought to be possible through the 
creation of an innovation eco-system in which a number of key elements interacted and 
provided support for each other.  One of the underlying principles of this idea was that the 
state should actively accelerate flagship projects and prioritise the provision of excellent 
infrastructure to facilitate innovation.   
As a direct result of the above reports, five higher education institutes (National University of 
Ireland Galway, University of Limerick, Dublin City University, University College Cork 
and the Royal College of Surgeons in Ireland) took the novel of step of combining their 
collective resources and expertise by agreeing to develop a medical device innovation 
programme (BioInnovate Ireland).  This venture was to be supported by a number of 
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stakeholders including Enterprise Ireland (EI) and the Irish Medical Device Association 
(IMDA).  
 
1.4 A brief summary of the BioInnovate Process 
As previously stated, BioInnovate Ireland is a specialist training program in medical device 
innovation and product design.  It is modelled on the Biodesign Fellowship program which 
has been offered at Stanford University, Palo Alto, California since 2001.  
Each year, two multi-disciplinary Fellowship teams are recruited.  Each team comprises four 
Fellows from either a medical, engineering, business, legal or technical graduate background.  
Over the course of a 10 month period, the two teams carry out their work in a number of 
distinct phases.  
 Identification of unmet clinical needs; 
 Inventing solutions to satisfy unmet needs; and  
 Implementing or commercialising some of the solutions identified.  
The 2011/2012 Dublin Fellows and their respective backgrounds were as follows 
Dublin BioInnovate Team  
Dr. Liam Mullins BE PHD  
Liam graduated with a degree in Mechanical Engineering from NUI, Galway in 2002.  He 
worked as a manufacturing engineer before starting a PhD in orthopaedic biomechanics at 
NUI, Galway in 2003.  In 2005 he attended UC, Berkeley as a visiting scholar where he 
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continued his research.  Throughout his PhD Liam conducted analysis and testing of medical 
devices and materials for industry. Liam published four articles from his PhD research and 
has continued research into the behaviour of Nitinol devices. 
Upon completion of his PhD research in 2007, Liam joined start-up Veryan Medical in 
Galway where he played a central part in the design of technologies to treat vascular disease. 
He has held roles with responsibilities in device design, animal trials, clinical trial design and 
biostatistics, finite element analysis, fatigue, manufacturing, patenting and market analysis. 
Liam is an inventor on four filed patents. 
He has also consulted for a number of medical device companies and clinicians on the design 
and analysis of medical devices. 
Dr. James McGarry BE, MB BCh BAO, MRCS, PhD  
James was interested in the application of engineering to medicine that began as an 
engineering student with an award-winning thesis on the biomechanics of cardiovascular 
stents.  He subsequently undertook a PhD at the Trinity Centre for BioEngineering with 
research periods in nanoscience, cell biology and bioengineering laboratories.  Convinced 
that dual training in engineering and medicine would yield a unique and valuable platform for 
innovation in healthcare, he chose to study medicine following completion of his PhD. 
James gained clinical experience in surgical posts, and was awarded the Membership of the 
Royal College of Surgeons examination.  As a doctor and bioengineer, the BioInnovate 
Ireland Fellowship was a unique opportunity to utilise his prior training, but also yielded a 
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new range of skills in the process of medical device innovation that were invaluable to his 
long-term goals. 
Ms. Vicky McGrath BE MSc MBA  
Vicky McGrath is a seasoned business professional with 15 years' experience in the medical 
device and diagnostics industry.  She was co-founder and head of business development at 
Argutus Medical where she was responsible for fund raising, strategy, planning, development 
and commercialisation efforts. Prior to Argutus, Vicky worked in operational and consulting 
roles at Abbott Labs, Biotrin International and Sabratek Corporation.  Vicky holds a BE in 
Mechanical Engineering from UCD, an MSc in Biomedical Engineering from Boston 
University and an MBA from the Smurfit Business School. 
Mr. Kevin Moore B.Comm LL.B  
After completing a B. Comm and then an LL. B. degree at NUI Galway, I spent seven years 
working with MG. Ryan and Co. Solicitors.  During that time I advised a large number of 
firms and drafted and negotiated many commercial agreements on behalf of corporate clients 
including start -up companies. I have practical experience of the most critical issues facing 
start-up companies particularly in the healthcare and life-science sectors including 
reimbursement, regulatory and intellectual property matters. During my career, I have 
regularly advised in the areas of incorporation, corporate structure, company secretarial 
matters, intellectual property rights, corporate governance and private and venture capital 
funding. I regularly advised on a number of commercial agreements.  I have also completed 
the Professional Practice Course at the Law Society of Ireland.   
“FROM UNMET CLINICAL NEED TO COMMERCIALISATION -THE BIOINNOVATE IRELAND 
PROCESS” 
 
 
11 
 
Personal Decision to apply for the Fellowship: The opportunity to have a positive impact on 
patient care was a particularly compelling reason to apply for the Fellowship. However, the 
Fellowship also offered me the opportunity to actively participate in the innovation process 
and to develop my interest in innovation, technology transfer, entrepreneurship and 
commercialisation. It therefore meant that would have a unique understanding of the medical 
device industry as a whole and would be better placed to form part of the ecosystem and 
support network envisaged for the medical device sector in Ireland.  
1.5 The Phases of BioInnovate 
1.5.1 Identification of unmet clinical needs 
Fellows are afforded the opportunity to make observations in a clinical setting for a period of 
eight weeks.  This process involves observing patients and healthcare professionals in a range 
of clinical settings including: specialist diagnostic clinics, surgical and interventional 
procedures, post-operative care and rehabilitation.  Challenges faced within the clinical 
setting are documented.  In this way, problem statements are defined and subsequently 
refined into needs statements which should adequately reflect unmet clinical needs.   
Needs are then filtered according to acceptance criteria which are designed by the Fellows.  
Typically, the top needs are validated through ongoing consultation with practitioners and 
relevant professionals.   
1.5.2 Inventing Solutions to satisfy unmet clinical needs  
A number of needs are then selected by the Fellow’s for this phase which involves ‘Ideation’ 
or the process of creating new concepts or ideas in order to provide solutions to one or more 
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well-defined unmet clinical needs. A key aspect of this phase is brainstorming. The ideation 
is carried out utilising group creativity and the diverse backgrounds and experiences of the 
Fellows are utilised to propose solutions overcome the challenges faced.  
 1.5.3 Implementing or commercialising some of the solutions identified. 
This is perhaps the most complex of the stages in the process and it involves taking steps to 
bring a new product to market. Valid needs are subjected to scrutiny in a number of areas to 
ensure that the solution is capable of being implemented by being brought to market.   
Among other things, this involves careful consideration of  
 Intellectual property landscape and strategy; 
 Reimbursement situation; 
 Regulatory affairs; and 
 Basic Business Strategy - marketing, sales and distribution. 
The Fellows bring concepts through to business planning, pitching to venture capitalists, 
early stage development planning and in some cases commercialisation.  
1.6 Conclusion - Can BioInnovate assist in fulfilling the vision of the Innovation 
Taskforce?  
As previously outlined, the innovation taskforce outlined a number of key steps which needed 
to be taken in order to fulfill its vision.  The BioInnovate Ireland programme addresses a 
number of these directly.  
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1. Supporting Innovators and Entrepreneurs – BioInnovate recruits a multi-disciplinary 
team of entrepreneurs who are funded and assisted for 10 months in their attempts to 
identify unmet clinical needs and propose solutions which are capable of 
commercialisation. These individuals are generally recruited from industry and take 
time out of their chosen profession. Without the support provided by BioInnovate 
most of the Fellows would not have the opportunity to explore their talent for 
innovation.     
2. Ensuring that our education system promotes education and innovation – A key part 
of the programme is a five-week ‘bootcamp’ in which the Fellows are given an insight 
into all of the important aspects of medtech innovation e.g. reimbursement, 
regulatory, intellectual property landscapes etc. In addition, a BioInnovation class is 
held each week. This is attended by the Fellows as well as a post-graduate class who 
are mentored by the Fellows. Both the Fellows and the post-graduate apply this 
knowledge in developing novel medical devices. This method of learning marks a 
new departure for the education system.  
3. Strengthening linkages between education and industry –Many of the sponsors and 
contributors to the programme are successful medical device companies such as 
Creganna -Tactx, Medtronic, Boston Scientific.  These companies have a vested 
interest in the technologies which are produced as a result of BioInnovate.  However, 
the benefits of collaboration go far beyond this. Sponsors also benefitted from 
learning about the innovation process adopted by the Fellows.  In turn, the Fellows 
also benefitted from the advice, direction and real-world experience of some of the 
most established medical device companies in the world.    
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4. Ensuring we have a world-class infrastructure - Perhaps the most important aspect of 
the programme is its ability to directly contribute to the med-tech infrastructure.  On a 
number of occasions during the Fellowship, presentations were made which were 
attended by researchers, clinicians, medical device companies, serial entrepreneurs, 
venture capitalists, reimbursements specialists, regulatory experts, legal advisors and 
intellectual property specialists. All of these supports are vital for a successful 
medical device eco-system as envisaged by the Innovation Taskforce. The importance 
of the fact that they are all available and are keenly aware of the role that they play 
cannot be over-stated if Ireland is to remain attractive as a medical device hub and is 
attractive for foreign direct investment. In addition, the programme produces Fellows 
educated in medical device innovation who will commercialise technologies or who 
will work directly within the industry.  
The following chapter documents the path taken by the Dublin BioInnovate team as they 
began the process of the identification of unmet clinical needs.  
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Chapter 2 
Needs Identification 
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2.1  Introduction   
As documented in Chapter 1, the team were given generous access to some of Ireland’s 
leading hospitals. However, the decision of how best to use this opportunity was a matter for 
the Fellows. Thus, the process utilised would be critical to the outcome of the project.   
2.2 Mission Statement 
Prior to commencing clinical immersion, the Dublin BioInnovate team prepared the 
following Mission statement.   
‘To develop innovations that have a positive impact on patient care while reducing 
system cost.’ 
It was important at the outset to identify what the team wished to achieve within the year and 
to reduce this to writing. In this way, when the Fellows began the BioInnovate process they 
would be under no illusions what they should be looking to achieve during clinical immersion 
and beyond. 
2.3 Locations for Clinical Immersion 
Needs identification took place on site in a number of hospitals. The teams were permitted to 
observe procedures and meet with clinicians, nurses, radiographers, staff and patients when 
required. Access to daily rounds and staff meetings was also permitted. However, the primary 
focus was on documenting observations which, in the eyes of the Fellows, appeared to 
present a problem for physicians. In effect, what is required by this stage is an objective 
perspective on work practices, procedures, processes and treatments which are not often 
subject to such scrutiny. It is important that validation takes places at a later date and that the 
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Fellows are not simply led by the opinions of third parties. Good observations should then 
provide the basis for well-described needs.  
The team were kindly permitted to make observations at the following locations: 
Dublin 
 St James Hospital 
 Beaumont 
 Blackrock 
Galway 
 UCHG 
 Galway Clinic 
Cork 
 Cork University Hospital 
 Mercy Hospital 
 Bon Secours Hospital 
It was felt important to make observations in different healthcare settings. The rationale for 
the Fellows was that if a problem was restricted to a particular institution, then it could not be 
said to represent an unmet clinical need.  
An effort was made to ensure that observations were made which spanned the cycle of care. 
An example of this involved interviewing a particular patient while they awaited a procedure. 
Arrangements were made to attend the procedures and the patient was interviewed following 
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the procedure in the intensive care unit and then on the cardiology ward as he continued his 
rehabilitation.    
It was decided by the Dublin team that every opportunity should be taken to observe as many 
procedures as possible and not simply to restrict the observation to the area of Cardiology. 
This reflected a belief on the part of the team that Cardiology is an area which has been the 
subject of a large amount of innovation in recent years. It was felt that taking every 
opportunity to observe all clinical areas possible would yield the best possibility of 
uncovering unmet clinical needs.  Therefore, observations were made in the following 
clinical areas: 
 Cardiology 
 Cardiothoracic surgery 
 Vascular Surgery 
 Neurology 
 Obesity Management 
 Urology 
 
 
 
 
 
 
 
“FROM UNMET CLINICAL NEED TO COMMERCIALISATION -THE BIOINNOVATE IRELAND 
PROCESS” 
 
 
19 
 
2.4 Recording Observations 
Needs Statement: A more effective and safer way to treat cerebral 
aneurysms with less recurrence
aneurysm
Observations to Needs (from 1,200 to 185 unmet needs)
Confidential
 Figure 2.1: A typical observation noted during clinical immersion 
 
Observations were documented at the end of each day and Google Docs was utilised for this 
purpose. This was a painstaking process, part of which involved reviewing observations of 
other Fellows to ensure that similar observations from the same procedure were only 
recorded once. Similar observations from different procedures or conversations were 
recorded separately in order to highlight issues that posed a problem across institutions and 
for many different patients or physicians. 
As detailed in Fig 2.1 above, Fellows were required to record the following in the initial 
stages: 
 A brief description of the observation; 
 A note of where the observation was made i.e. was in it a procedure or in 
conversation; 
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 The date of the procedure; 
 The name of any physician involved.  
At the end of the eight weeks of clinical immersion, the Dublin BioInnovate team had 
compiled over 1,200 observations.  
2.5 Conclusion 
The willingness of medical professionals to engage with the BioInnovate process is obviously 
crucial.  It was found that, without exception, clinicians were willing to engage with the 
process when they understood that the end goal was the advancement of patient care.  Until 
this fact was pointed out, clinical immersion was a less fruitful exercise.  A useful method 
would have been to present an overview of the process at a staff meeting early in the clinical 
immersion.  
At the outset, the Dublin Fellows had set a goal of obtaining over 1000 observations during 
the clinical immersion phase. It has been generally accepted within previous Biodesign 
Fellowships that over the course of two months of clinical observation, 1000 observations is a 
legitimate target and moreover, is a necessary target required in order to eventually produce 
the unmet clinical needs required. Observations will not always represent legitimate problems 
and even legitimate problems will not always represent unmet clinical needs which are worth 
pursuing.  The decision to observe procedures across a variety of clinical areas played a vital 
role in achieving this target.  Had the focus been restricted to the Cardiology department, the 
likelihood is that there would have been downtime in waiting to see relevant procedures or to 
speak to clinicians.  In addition, it is rarely possible to facilitate four observers into an 
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operating theatre or a clinic.  The strategy to avoid these difficulties meant that the Fellows 
were rarely left without an opportunity to make observations.   
However, this also meant that the observations were obviously drawn from a wide number of 
areas and this would have implications for filtering the observations and translating them into 
unmet clinical needs. This process is explored in the following chapters.  
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Chapter 3 
Translating observations into unmet 
clinical needs 
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3.1 Introduction 
The needs filtering process was perhaps the most challenging aspect of the BioInnovate 
process. This chapter explores the reasons for eliminating various problems identified in 
order to arrive at a list of the top 10 unmet clinical needs.  
3.2 Filtering phases 
At the beginning of this process, the Dublin team began with over 1,200 observations/ 
problem statements which reflected the difficulties that had been observed. 
By the end of this process, the Fellows hoped to become experts on a chosen few unmet 
clinical needs. There was a realisation that this could not be done on a large number of needs. 
At the outset therefore, there was recognition that a number of filtering mechanisms would 
need to be applied.  
There was agreement between the Fellows that filtering would be an ongoing process but that 
it should be divided into a number of phases: 
 Phase 1: Needs (roughly defined based on clinical immersion observations) were to be 
initially be filtered based on:   
1) Impact on patient care; 
2) Propensity to reduce costs; and 
3) Market size. 
 Phase 2: A more detailed assessment of criterion 1-3 in Phase 1 was performed. Clinical 
feasibility which is discussed below in terms of the burden of proof for potential solutions 
was also considered. A deep-dive fact -based assessment was performed on each rough 
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need in areas including disease state, epidemiology, market analysis, pathogenesis, 
causes, risk factors, presentation, diagnostic tests, current medical management, current 
surgical or interventional management, key clinical outcomes/endpoints, current 
effectiveness of treatments, trial duration, potential for cost reduction and market 
size/growth. The rough needs were then appraised and changed or deleted accordingly.  
 Phase 3: This took place concurrently with brain-storming and included further clinical 
validation and input from seasoned clinicians, med-tech and business professionals. A 
thorough competitor analysis, stakeholder analysis and assessment of the current 
reimbursement situation were performed. Regulatory burden, IP concerns, and 
technological feasibility which were not addressed in detail in Phase 2 were to be 
assessed.  
The following figures set out the mechanisms by which Phases 1 and 2 detailed above were 
achieved.  
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The BioInnovate filtering process – an overview
Observation
s to Needs
• >1,200 observations distilled to 185 needs
Preliminary 
Filtering
• 185-80
• Market, Patient Impact, Cost Reduction
• Market Dynamics – growth prospects, major 
competition
Deep Dive,  
and Burden 
of Proof
• 80-10 completed on Dec 22nd 2011
• Current management, mechanisms, epidemiology etc
• Clinical trial feasibility
N
eed S
tatem
ent  
R
efinem
ent
R
ough 
N
eed
Confidential
Figure 3.1: The BioInnovate filtering process – an overview 
 
 
3.3 Observations to needs 
The first step in this process required eliminating a number of observations.  It was decided 
that observations under the following headings were outside the scope of what the team 
wished to achieve: 
 Information Management or IT-only projects – During clinical immersion, a great 
many problems arose because of the fact that IT systems across institutions were not 
compatible. Even within hospitals, hand-written notes were often used when 
recording patient data and this would need to be inputted into the system later on or 
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even utilised by other members of staff. It was felt by the Fellows that relevant 
technologies to meet these needs already existed so perhaps the will was not there to 
change systems.  Also, within the team there was no I.T. expert and therefore it would 
be unlikely that the team would achieve solutions to these problems. 
 Logistical issues - There were a number of difficulties with the flow of good medical 
products and patients. For example, on ward rounds, it often took a long time for 
doctors to locate their patients who had been placed in any ward where there was 
space.  It was felt that dealing with these logistical matters would not bring about the 
improvements to patient care that the Fellows were looking to bring about. 
 Ergonomics – There were a number of observations which arose out of sub-optimal 
working environments.  For example, staff in hospitals had a great deal of difficulty 
moving patients onto and off beds on which they had been treated in various theatres.  
Once again, it was felt that dealing with ergonomics would not bring about the 
improvements to patient care that the Fellows hoped to achieve. 
 Imaging – In a number of settings, including the catherisation lab, interventional 
radiology, vascular surgery and neurology, it was observed that the quality of imaging 
used by physicians to view positions within vessels were often quite poor. Many 
observations were made around the inability to confirm that treatment had been 
effective. Improved imaging and mapping has the potential to impact hugely on 
patient care. However, it was felt that the skills did not exist within the team to bring 
about improvements in the area and that the expertise of the large players in the 
market may prove too strong. 
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After the elimination some observations as detailed above, every remaining observation was 
considered. As a group, the Fellows made a decision as to whether each observation 
represented a truly unmet clinical need or something that was simply less than ideal or a ‘nice 
to have’.  Observations falling into the former category were assigned a ‘1’ and brought 
forward.  The latter were assigned a ‘0’ and disregarded at that stage. 
3.4 Need Statement Development  
Concurrently, every problem statement was refined into rough need statement. Need 
statement development was a critical aspect in the process.  
The aim was to clearly articulate a need so that the parameters would guide the development 
of concepts and potential solutions.  It was felt critical that the needs statement would address 
what change in outcome was required and not how it would be addressed. Therefore, no 
potential solutions could be reflected in the need statement. 
Additionally, Fellows were keen to define the scope of each need statement correctly, 
conscious that a narrowly defined statement could miss a potentially large market or that a 
statement which was too broadly defined would not articulate the need correctly.   
 
3.5 Preliminary Filtering 
It was next decided that the remaining 185 roughly drafted needs would need to be ranked. In 
this regards, the Mission Statement was utilised to develop the filters that adequately reflect 
what needed to be achieved.  Essentially these meant that a number of parameters would need 
to be met before a project could be taken forward. 
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Preliminary Filtering (from 185 to 80 unmet needs)
Market Size
1:  <  250 m
2:  250 m to 500 m
3:  500 m to1 bn
4:  1 bn to 2 bn
5 :  2 bn
Patient Impact
1: No change
2: Reduction in peri/ post-operative pain
3: Some change in clinical outcome
4: Change in QOL/ some reduction in deaths
5: Massive improvement in QOL, reduction in 
deaths
Potential for cost reduction
1: None
2: Minimal
3: Some
4: ...
5: Massive reduction in cost (e.g. stroke)
Confidential
Figure 3.2 Preliminary Filtering (from 185 to 80 unmet needs) 
Each need was allocated a figure based under each of the above headings and therefore 
received a ranking as outlined in Fig 3.3 below. 
Preliminary Filtering (from 185 to 80 unmet needs)
Confidential
Figure 3.3 Continued Preliminary Filtering (from 185 to 80 unmet needs) 
The result of this process meant that the 185 needs were further reduced to a top 80 unmet 
clinical needs.  
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3.6 The Deep Dive 
In arriving at the top 80 needs, time constraints meant that rankings needed to be allocated on 
the basis of limited information.  For example, a cursory look at the current and projected 
future markets for cerebral aneurysms was used to allocate a figure for that market.  There 
was a consensus amongst the Fellows that in order to make satisfactory progress, a more in-
depth analysis of the needs would be required.  
On that basis, all of the needs were grouped into relevant clinical areas e.g. peripheral 
vascular, obesity management or structural heart.  Each of the Fellows were assigned clinical 
areas with responsibility for conducting an in-depth analysis of the disease state and how it is 
currently managed. 
Detailed information was gathered under the following headings: 
 Epidemiology 
 Pathology 
 Causes and Risk Factors 
 Patient History/ Presentation/ Symptoms 
 Diagnosis 
 Current Treatment Guidelines 
 Medical Management 
 Surgical/Interventional Management 
 Effectiveness of Treatment 
 Perceived inadequacies of current management 
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 Devices/Drugs/ procedures in the pipeline which might meet the current unmet 
clinical need  
The breadth of clinical areas considered meant that the review took a number of weeks.  The 
Fellows would present their findings back to the group and based on this and the discussions 
and further research that ensued, each need was assigned a mark under the various headings.  
This in- depth analysis of the disease state and its management allowed the Fellows to better 
understand each need as well as establish which needs presented a better opportunity e.g. if a 
need for a medical device was already served by medical management techniques this was  
seen as less of an opportunity than a need with no current solution  
3.7 The burden of Proof 
As detailed above, during phase two, the Fellows opted to include a Clinical Feasibility 
Filter.  It was felt that in order to have a product that was capable of commercialisation, it 
would be necessary to be able to show an effect.  Preferably quickly and easily.  Therefore, in 
each area, current clinical trials which are ongoing were assessed and used to objectively 
predict the type of trial that a regulatory body would be likely to require before a product was 
brought to market.  The headings used were as follows: 
 Trial Duration: This heading addressed the time that would be required to show an 
outcome in a patient group.  For example, if it might be possible to confirm that a 
particular need had been addressed peri-procedurally or in the hours thereafter, then 
the need would score highly.  However, if some years were required to show that a 
patient’s symptoms had reduced over time, then the need would not score well in this 
area.     
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 Endpoint: Clinical endpoints are used to measure whether the target outcomes of a 
trial have been achieved.  The ease with which these can be measured will go a long 
way towards assessing the success of the trial.  For example, if the endpoint is a 
reduction in pain following thoracic surgery, this will not be easily measured. 
However, the ability to reduce the incidence of stroke after trans-catheter aortic valve 
implantation (TAVI) is more easily measured and would score higher in this area.    
 Difficulty in proving efficacy: This points to the effort required to show that an 
improvement can be shown statistically. Essentially, the lower the desired 
improvement rate, the greater the number of patients which will be required to be 
recruited and therefore the cost of the trial may become prohibitive to the 
commercialisation process.  
Predicting the type of trial which may be required before a concept has been generated is a 
difficult but very useful process. Each of the headings mentioned above have huge 
implications for the cost and difficulty of a clinical trial.  Any start-up company looking for 
funding will be hindered in its efforts to secure funding if a trial is likely to be of too great a 
duration or the outcomes are uncertain.  It was felt important to ensure that any product 
developed would be in an area where it was possible to show a clinical benefit quickly and 
expediently.     
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Figure 3.4: Snapshot of needs statements and scorings awarded in the area of Stroke after the 
Deep Dive.  
 
3.8 The Top 20 Needs 
After the assignment of final marks and the addition of a mark for clinical feasibility, the 
team was left with 20 top needs at the end of 2011.  
Stroke (acute) Stroke (preventative) 
Need statement(s) 
An easier and more effective 
safer way to remove a 
cerebral thrombus causing 
stroke (97, 179, 147) 
A way to prevent 
cardioembolic stroke (68) 
  
A way to prevent 
complications due to 
reperfusion injury following 
delayed revascularisation in 
stroke (176) 
A need for an improved 
method of preventing 
thrombus formation and 
migration (99) 
Original Identifiers 97, 147, 176, 179 68, 99 
Redefined need statement (if any change) 
A way to improve 
revascularisation, 
reperfusion injury and 
clinical outcome in acute 
stroke intervention. 
A way to prevent 
cardioembolic stroke 
      
Clinical Trial Feasability (0 to 15)     
Time Required to Show Outcome (5 <24hrs; 
4<3mts, 3=6mts to 1yr; 2=1yr to 2yrs, 1>2yrs) 4 2 
Endpoint is easily defined, measured, and has 
high specificity 5 5 
Difficulty proving efficacy (statistically and ability 
to recruit, 5 > 50 patients, 4 > 100 patients, 3 > 
200, 2 > 400, 1 > 500)  4 1 
Total =  13 8 
      
Market Size (0 to 15) 12 12 
      
Patient Impact (0 to 15) 15 15 
      
Cost Reduction (0 to 15) 15 15 
      
Competitive Landscape      
Competition & Incumbents     
      
Overall total (out of 60) =  55 50 
Rank 1 6 
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A need for a minimally invasive way to treat carotid artery disease, with reduced incidence of stroke  
A more reliable and cost-effective way to close a femoral arteriotomy during an interventional procedure  
A need for a more effective and efficient method for closure of a laparoscopic port site, particularly in the 
obese  
An improved way to treat chronic total occlusions using interventional techniques  
A more effective and less painful way to treat varicose veins  
A way to prevent persistent air leaks due to lung resection  
An improved way to recanalise ‘below the knee’ peripheral arterial disease  
A more reliable way to seal a gastrointestinal anastomosis  
A way to prevent or treat pressure ulcers in immobile patients  
A need for a less invasive alternative to surgery in improving survival in severe COPD  
A way to treat and prevent recurrent atrial fibrillation  
A way to prevent seeding of carcinoma during percutaneous biopsy and treatment  
A way to treat chronic venous insufficiency  
A way to prevent stroke during and after transcatheter aortic valve implantation, during the high risk period  
A way to prevent reperfusion injury following revascularisation in ischaemic stroke  
A way to mitigate injury due to delayed revascularisation in ischaemic stroke  
A way to treat complex cerebral aneurysms  
A way to treat/prevent the complications associated with cirrhosis  
A way to improve costs and outcomes in dialysis access  
A way to prevent heart failure after myocardial infarction  
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3.9 Conclusions 
The ability to make informed decisions under time constraints is a critical skill. Distilling 
1,200 observations to 185 unmet clinical needs in a number of weeks will provide a challenge 
for any team.  Over-reliance on instinct will almost certainly lead to the elimination of key 
observations at an early stage.  The selection of filtering criteria and the establishment of 
parameters by which each need is evaluated proved critical to the process utilised by the 
Dublin Fellows.   
Furthermore, the concept of need statement development mentioned above cannot be 
understated.  As stated above, good observations form the basis for well-described needs.  
For example, it is often said that a common mistake of previous Biodesign Fellows had been 
to incorporate elements of solution into a needs statement. While it is understandable to wish 
to reference potential solutions in these early stages of the process, the effect is to narrow the 
focus of the team and limits the possible opportunities explored in due course. The 
experience of the Fellows was that the description of needs evolved continuously as new 
information comes to hand during the deep dive.  By constantly reviewing their work, the 
Fellows felt that the needs were properly described at the end of the process.  The next 
chapter examines the background to one of the unmet clinical needs identified as well as the 
opportunity it presented.  The remaining chapters explore the premise that a problem is half 
solved if properly stated.   
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Chapter 4 
Project Profile: A way to treat 
complex cerebral aneurysms 
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4.1 Introduction 
This chapter gives a background from one of the unmet clinical needs which was investigated 
by the Fellows and brought forward to the brainstorming stage.  It is a summary of much of 
the information which was uncovered during the ‘deep dive’ conducted by the Fellows and it 
is constructive in terms of the level of detail which was required for each of the top unmet 
clinical needs.  
4.2 The observation  
In general conversation with an interventional radiologist, Dr. John Thornton, it was noted 
that ‘the risk of rupturing an aneurysm when coiling is about 2-3%.’  This information 
prompted the Fellows to investigate cerebral aneurysms, arrange to view some interventional 
procedures and interview experts and key opinion leaders in the field. 
4.3 The background - Cerebral Aneurysms  
A cerebral or brain aneurysm is a disorder of the cerebral vasculature. In short, a weakness in 
the wall of a blood vessel of the brain, leads to dilation or a bulging outwards of the vessel. 
Small aneurysms are generally classified by physicians as less than 15mm in diameter.  
In the event that an aneurysm grows larger physicians advise that this can lead to symptoms 
such as:  
 severe headaches 
 nausea  
 loss of vision 
 loss of consciousness  
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 Vomiting.  
However it is not uncommon for some patients with large cerebral aneurysms to remain 
asymptomatic.  
From viewing medical procedures it became clear to the Fellows that cerebral aneurysms 
vary greatly in terms of size or shape which makes it difficult to predict how they are likely to 
develop and behave.  The American Heart Association / American Stroke Association (the 
Stroke Association Website, November 2012) classify cerebral aneurysms through their size 
and shape as follows: 
Size 
 Small aneurysms are less than 5 mm (1/4 inch). 
 Medium aneurysms are 6–15 mm (1/4 to 3/4 inch). 
 Large aneurysms are 16–25 mm (3/4 to 1 1/4 inch). 
 Giant aneurysms are larger than 25 mm (1 1/4 inch). 
Shape 
Aneurysms can be: 
 Saccular (sac-like) with a well-defined neck 
 Saccular with a wide neck 
 Fusiform (spindle shaped) without a distinct neck 
Over time, if aneurysms grow larger, the risk of rupture increases as the wall of the vessel 
becomes thinner.  
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If this situation occurs, a subarachnoid haemorrhage can occur whereby blood leaks into the 
spaces surrounding the brain.  In addition, a bleed directly into the brain causes haemorrhagic 
stoke.  Damage to the brain typically occurs quickly and complications can include 
permanent neurological damage, hydrocephalus and vasospasm.  The risk of mortality is 
extremely high.   
Cerebral aneurysms are relatively common, with an estimated prevalence of 1 to 5% in the 
general population.  Although 50 to 80% of all cerebral aneurysms do not rupture, when they 
do the results are devastating for patients.  The estimated incidence in the US is 27,000 cases 
per annum). 30 day mortality is 45% and 30% of survivors have moderate or severe 
neurological deficits. (Brisman, J.L., Song, J.K., Newell, D.W. Cerebral Aneurysms. N Engl 
J Med 2006; 355: 928-39.)   For these reasons, screening programs have been established to 
determine at-risk individuals, in particular those with a family history (two immediate 
relatives with intracranial aneurysms) or a diagnosis of polycystic kidney disease (the Stroke 
Association Website, November 2012).  
The brain is particularly sensitive to bleeding and damage can occur very rapidly, often 
resulting in death.  According to estimates, approximately 40% of those whose aneurysm 
rupture do not survive the first 24 hours, with about 25% dying from complications within 6 
months (Patient Information Publications).  
4.4 The current treatments 
If a patient with an intracranial haemorrhage (ICH) is rapidly transferred to a hospital, they 
may undergo emergency surgery to stop the bleeding, provided by either a neurosurgeon, 
with clipping, or a neurointerventional radiologist, with coiling.  The success of such 
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treatment will be highly dependent upon the amount of damage that has occurred.  The 
consequences of an ICH are so serious and the outlook is so poor that aneurysms which are 
deemed to be at high-risk for rupture (in accordance with international treatment guidelines) 
may be treated electively before they ever rupture.  In certain circumstances, particularly with 
critically ill patients, or really complex aneurysms surgical clipping may be required, 
although this approach is generally only used in a small percentage of any patient population.  
 4.4.1 Coiling 
Coiling is the less invasive of the two treatments.  However, it should be remembered that not 
all aneurysms are suitable for coiling. In either the emergency or the elective setting, 
endovascular coiling (‘coiling’) is the current treatment of choice and has existed for upwards 
of twenty years.  Covidien, Johnson and Johnson, Stryker and Terumo are all examples of 
large corporations involved in the production of coils for use in neurovascular procedures.  
Coiling is a minimally invasive procedure (under sedation at most).  The tiny coils are 
delivered through a catheter that enters the arteries in the brain via an artery in the groin. 
Coils are inserted into the aneurysm one by one, through the catheter, until the sac is full of 
coils and causes a clot to form in the sac, thereby preventing additional blood from entering 
the aneurysm.  When a thrombus has been caused to form and fill the sac, further expansion 
of the aneurysm is thereby prevented.  Coiling has become widely used and has been shown 
to be superior to surgical clipping in the emergency setting, with reduced morbidity and 
shortened hospital stays (Brisman et al).  
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As mentioned above, coiling works well for simple aneurysms (those with a narrow neck) 
because the coils are easily kept inside the sac without any need for further assistance. 
However, coiling has a number of limitations:  
1. Very large, wide-necked or irregular shaped aneurysms are difficult to treat with 
coiling and interventionalists often have to use balloons (as a temporary platform) or stents 
(as a permanent platform) in the vessel, through with the coils are delivered.  The platform 
provides the necessary support to prevent the coils from exiting the sac and causing a clot, or 
even occluding the parent artery.  Using these additional tools requires tremendous skill and 
can be very time consuming.  The techniques are used in an estimated 30% of all coiling 
procedures (Millenium Research Group. US Markets for Transcatheter Embolization and 
Occlusion Devices 2011.) 
However, in a number of cases this is the only treatment option.  In an emergency ICH 
situation only balloon assisted coiling can be used (stent-assisted coiling is contra-indicated 
in an ICH as patients with a stent must be put on medication that further increases the risk of 
bleeding), with limited success because of the time required to complete the procedure and 
thus stop the bleeding.  It follows that the risk of neurological deficits increases significantly 
with continued bleeding.  
2. The costs associated with coiling, both in terms of material costs and time, can be 
significant, particularly for large aneurysms that require multiple coils to fill the sac. 
Typically a single coil ranges in price from $500 to $3,000 (Cloft, 2009).  Treating a large 
aneurysm that requires 10 or 20 coils, and possibly a stent (~$5,000), can be extremely costly 
(Cloft, 2009).  An analysis of a submission by Covidien in support of its Pipeline 
Embolisation Device to the National Institute for Health and Clinical Excellence (NICE) in 
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the UK, details the costs associated with treatment of unruptured complex aneurysms as 
follows (NICE, 2011): 
Intervention Procedure cost 
Pipeline embolisation device  £24,341 
Stent-assisted coiling  £37,451 
Neurosurgical clipping  £11,658 
Conservative management  £10,352 
  
4.4.2 Flow Diverters 
As the name suggests, these devices are used to ‘divert flow’ away from an aneurysm.  This 
is achieved by inserting a stent-like device into the lumen of a parent vessel which prevents 
the flow of blood into the aneurismal sac.  In this way, the inter-saccular blood forms a 
thrombus thereby achieving the same result as the insertion of coils into an aneurysm.  
Flow-diverters are particularly suited to treating rare fusion aneurysm where bulging occurs 
along the circumference of the vessel and giant aneurysms with wide necks which may not be 
suitable for the retention of a coil. 
Although flow diverters are often compared to stents, they are actually required to have much 
more material than a traditional stent to that they can achieve their aim of the prevention of 
blood flow into an aneurysm.  
Flow diverters are currently extremely expensive. In the UK, average flow-diverter prices are 
estimated at (£10, 171) by Covidien, one of the main manufacturers: Nice: Medical 
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Technology, Guidance assessment report overview - Pipeline embolisation device for the 
treatment of complex intracranial aneurysms 2011.  
Through interaction with a number of clinicians who are key opinion leaders in this field, it 
was noted that there has been experience of a high rate of complications including rupture, 
migration, thromboembolic occlusions and blockages of other vessels (perforator branches). 
Flow-diverters also by their nature, lead to the introduction of large amounts of intra-luminal 
thrombogenic material into the vascular system, leading to long-term dual anti-platelet 
therapy.  
Another restriction is that flow diverters do not permit a clinician to confirm peri- 
procedurally that occlusion has been achieved.  They are therefore unsuitable for use in 
emergency procedures.  
4.5  Future Competition 
Through an analysis of the intellectual property landscape, two emerging technologies of note 
were identified: 
 4.5.1 Sequent Medical Woven Endobridge II (Web II) 
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This device consists of a mesh which is designed to occlude wider – neck saccular aneurysms 
of particular sizes.  Devices have been made which are suitable for treatment of aneurysms 
between 5 and 11m in diameter.       
4.5.2 NFocus Neuromedical  - the Luna Aneurysm Embolization system  
(Luna AES) 
  
 
This device is another intra-saccular device.  It is a self-expanding ovid braided intra-saccular 
thrombogenic implant device that provides an attenuated mesh of metal across the neck of the 
aneurysm. 
Benefits of the Sequent and Luna devices include their ability to be positioned within the sac, 
treatment of the aneurysm in a single step and faster occlusion times.  The primary criticism 
is that pre-procedural accuracy in sizing is essential and if underestimated, blood may 
surround the device within the sac leading to recurrence, or parent vessel occlusion.  It is 
under-sized, the interventionalist has limited time to retrieve the device via the delivery 
catheter or the risk of a thromboembolism becomes critical.  
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4.6 Conclusion:  The Unmet Need and Opportunity  
From speaking to clinicians and observing procedures and researching literature, it became 
obvious that the current treatment methods for dealing with complex cerebral aneurysms are 
not ideal.  Apart from the risk of rupturing an aneurysm peri-procedurally, there were many 
other drawbacks.  Therefore, there existed an opportunity to create an alternative to current 
treatment mechanisms.  However, any solution would need to be  
 Safer 
 More effective 
 Less expensive 
 Less time – consuming. 
The efforts made to identify a solution in this regard are detailed in the following chapter.  
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Chapter 5 
Invent 
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5.1 Introduction 
As detailed above, from the top twenty unmet clinical needs, eight needs were selected by the 
Fellows for brainstorming.  This chapter details the process utilised and the solution proposed 
for the cerebral aneurysm referred to in Chapter 4.  
5.2 Appraisal for brainstorming 
Rather than selecting the tops needs, all needs were appraised as follows: 
 Consideration of technological and clinical risk – If it was felt that working in a 
particular area was not technologically feasible then this would pose obvious 
difficulties.  Clinical risk was seen as something which might always exist with any 
novel technology but it was a factor to be noted.  
 Size of the project and the probable time to exit - If for example, the project was to 
involve the development of a heart valve, then the time to exit and cost of the project 
may prove prohibitive in securing funding as it would be an unattractive proposition 
for a venture capitalist. 
 One opportunity suitable for licensing was to be brought forward – the goal of this 
project was to ensure that at least one project which was capable of 
commercialisation by the Fellows themselves would be produced.  However, if one 
compelling solution was produced which was more suitable to be licensed externally 
to the group, then this would be considered.   
 Skill set within the team - It was deemed important that the expertise to 
commercialise a solution was readily accessible within the group.  
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 Fellow’s interest – it was a pre-requisite that passion and interest in the project was 
required in order to make it a success.  
5.3 Ideation  
As mentioned in Chapter 1, ideation was carried out utilising group creativity and the diverse 
backgrounds of the Fellows.  Brainstorming was therefore conducted as a group and in a 
variety of locations to encourage creativity.  All Fellows were encouraged to participate 
equally.  
At the outset, all potential approaches, no matter how feasible were suggested and a list was 
compiled.  Ideas were suggested in a rapid fire manner with the emphasis being on wild ideas 
and novel approaches.   
After this process, the various ideas were presented visually and appraised for their possible 
clinical benefit and technical feasibility.  
5.4 Continued interaction with clinicians  
Contemporaneously with brainstorming, every opportunity was taken to meet with clinicians, 
venture capitalists and key opinion leaders to seek further information and opinions.  
Typical examples of questions asked of physicians involved in the area of cerebral aneurysms 
included the following: 
 What effect would reducing the blood flow have on the aneurysm? 
 Will pipeline devices require antiplatelets beyond 6months? 
 What causes the weakness in the wall of an aneurysm? 
“FROM UNMET CLINICAL NEED TO COMMERCIALISATION -THE BIOINNOVATE IRELAND 
PROCESS” 
 
 
48 
 
 What is the weak point of the aneurysm? Is it at the neck or elsewhere and would 
strengthening of wall help? 
 How many aneurysms remain untreatable despite the addition of Flow diverters to the 
toolbox of a neurovascular interventionalist? 
 Do the flow diverters migrate much, and if so does this scare you? 
 Is perforator occlusion a problem with flow diverters?  
 How unacceptable is the use of anti-platelets in your experience?  
 Are perforators actually staying patent with Flow diverters? 
 Would a solution which cannot be assessed for technical success during a procedure 
be appropriate? 
 Given the high rate of restenosis for stents, to what degree can the cerebral vasulature 
tolerate some kind of anchor? 
 With less material in a device, is shorter interval of (or no) antiplatelets acceptable?  
 Are there dangerous aneurysms out there being left untreated for want of a device that 
can be used in more complex aneurysms?  
 Is peri-procedural confirmation of occlusion a 'nice to have' or seen as necessary? 
 Is there always a follow-up procedure to evaluate progress? 
 Does the shape of aneurysms vary greatly? Does this cause further difficulty in 
treatment?  
 How often are these aneurysm monitored?  
 Is coiling acceptable treatment for narrow-necked aneurysms or do you believe that 
coiling might be replaced by flow diverters? 
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 Do you see a future role for stent assisted and/or balloon assisted coiling into the 
future? 
 Do you think flow diverters on their own will be adequate or are you looking at a 
combination of diverter & coiling? 
 What has the clinical experience been with 1) Onxy and 2) Trufill?  
 How long does it take for Onyx and Trufill to cure? 
5.5 In-depth analysis of Competition  
Reference was made in the previous chapter to the emerging technologies which were briefly 
reviewed.  In order to inform the brainstorming, more detailed analysis of those technologies 
was continued by the Fellows.  A sample of the information compiles on the Sequent Web –
Woven Endobridge Cerebral Aneurysm device is provided below:    
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5.6 The Design Principles  
From the information during the process, it was clear that a number of design principles 
would need to be established.  These were as follows: 
Sequent Web - Woven Endobridge Cerebral Aneurysm Device  
First in Man study attempted to measure immediacy, degree and durability of aneurysm occlusion.  
Implanted in one unruptured MCA trifurcation aneurysm and one patient with an unruptured basilar tip 
aneurysm.  
Results:  
 Delivery and deployment of the WEB II device was technically straightforward and achieved 
without complications.  
 Neither device required retrieval or repositioning after full deployment.  
 There were no peri-procedural thrombembolic or hemorrhagic complications. 
 In both cases, complete aneurysm occlusion was observed within minutes of device deployment.  
 Short-term angiographic follow-up confirmed stable complete occlusion at 8 weeks. 
Notes: 
 The device is designed with a concave base to avoid the formation of thrombus on the device. 
Patients only required aspirin (100mg six months) and heparin (3 days). 
 The structure of the WEBII was designed for large neck aneurysms. The device is indicated for 
the treatment of saccular aneurysms with a neck-to dome ratio of  ≤1 and a neck length-to-width 
ratio of <2,where the neck length-to-width ratio is the ratio of the longest neck diameter divided 
by the shortest neck diameter.  
 Devices available in varying sizes to treat aneurysms from 5mm to 11 mm in diameter. 
 Series B funding received -$15.5 Million. 
 Series C funding received - $26 Million. 
 6F catheter required.  Standard 0.027 micro catheter used to deliver the device itself. 
 Patient 1: 3 mins to device deployment after placing catheter in aneurysm.  Stasis in aneurysm 
10 mins after deployment. 
 Patient 1: appears to have had a narrow neck but a high AR (5.5 width, 2.1 neck). 
 Patient 2: Aneurysm measured 7× 4.6 mm with a 3.35-mm neck. 
 May be better than coiling - First, better at creating the endoluminal overgrowth of neointimal–
neoendothelium at the aneurysm– parent artery interface.  Which probably means greater rates of 
complete occlusion with lower rates of delayed re-canalization following treatment.  Second, the 
amount of device manipulation within the aneurysm sac is reduced, particularly for large 
aneurysms. 
 Has not yet been used in the most common aneurysms found.  MCA bifurcation represent 20% 
of all cerebral aneurysms. Basilar Artery 7%.  
 Patient 2: 13 mins to deployment from catherisation of aneurysm.  
 If the operator decides that the sizing or orientation is not favourable, the device needs to be 
immediately resheathed/removed/repositioned.  
 If the device is over-sized relative, it could push out through the aneurysm neck (the path of least 
resistance).  
 The neck cannot exceed the device diameter.  
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 The invention needed to induce thrombosis within an aneurysm sac only; 
 The risk of damage during and after the procedure had to  be minimised; 
 There could  be no thromboembolic occlusion of the parent artery; 
 The invention would ideally be inexpensive; 
 The invention had to be capable of treating ‘hard to treat aneurysms’; and 
 The inventions had to be capable of treating regular aneurysms. 
The experiences of the Dr. Liam Mullins in previously designing medical devices and the 
experiences of Dr. James McGarry in previously using medical devices were invaluable in 
the establishment of these design principles.   
5.7 The Proposed Solution (s)  
 
Figure 5.1: Sketches of complex cerebral aneurysms that may be difficult to treat by 
unassisted endovascular coiling. 
Solution 1: Stabilising wings:  To keep the occluding material in the sac, an expandable 
shape memory frame that sits on either side of the sac in the parent vessel was devised.  This 
frame anchors the material in place by extending along the length of the parent artery and 
providing geometric stability.  Unlike a stent, anchoring is achieved with minimum damage 
to the parent vessel wall.  The area of contact and therefore endothelial injury will be far less 
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with this design.  The frame is symmetric with two wings and a central portion that attaches 
to a body within the sac, or to a lid over the sac.  The lid design could therefore be used as an 
adjunct to coiling or as an alternative to stenting.  A considerable advantage is that long-term 
antiplatelet therapy would not be required as endothelial injury would be minimal in attaining 
stability.  
 
Figure 5.2: Stabilising wing sketches.  
Expanding stabilising symmetric wings keep an intra-saccular component in 
position within the aneurysmal sac. (Inset: Sketch of a cross-section of parent 
vessel artery illustrating the typical degree of strut-wall area of contact, and 
therefore minimal risk of wall injury or thrombus formation in the parent vessel.) 
Solution 2: Compliant intra-saccular bag.  A compliant (possibly double-walled) 
bag is advanced in to the sac by catheter delivery and allowed to fill with, for 
example, blood.  The bag is compliant and occupies the irregular aneurysm shape, 
becoming flush with the aneurysmal sac wall.  The bag may be limited in size such 
that it does not fill the entire sac.  A double-wall design would allow a thin layer of 
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adhesive to be introduced in between the two walls of the bag.  Perforations in that 
portion of the outer wall of the bag that lies within the aneurysmal sac would allow 
the adhesive exit the inter-wall bag space and cause the external surface of the bag 
to adhere to the inner wall of the aneurysmal sac.  The surface of the bag forming a 
border with the parent vessel has no perforations, and simply hardens to form a solid 
surface.  A supporting balloon or temporary lid may be used to provide the desired 
support and shape for the hardening bag wall along the parent vessel. The thrombus 
containing bag and any adhesive will be made of materials that are both 
biocompatible and are reabsorbed, such that with time and healing the treatment will 
be integrated into the vessel wall.  Other embodiments of a similar principle include 
the use of foams with channels for transporting adhesive to the interface with the 
sac wall. 
 
Figure 5.3: Compliant intra-saccular bag sketches 
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5.8 Conclusion 
The process required the Fellows to, once again, delve further into the particular disease state 
during the invention stage.  The result of this was a solution to an unmet clinical need. 
Traditionally, medical devices are invented or produced at which point it becomes necessary 
to begin work on distinguishing them from their competitors or establishing their novelty.  By 
the nature of the process followed, much of this work had already been accomplished by the 
Fellows.  
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Chapter 6 
Project Activity Decision and 
Conclusion 
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6.1 Introduction 
This chapter details the status of the project detailed in the foregoing chapter by the end of 
the process in May 2012. It also offers a reflection on the success of the process followed by 
the Dublin team. 
6.2 Project Activity Decision 
At the outset, it had been envisaged by the Fellows that an output of the programme would 
take the form of one or more business plans.  Time constraints meant that it would not be 
possible to achieve this by the time the Fellowship drew to a close in May 2012.  Therefore, it 
was deemed prudent to compile the basic elements of a business plan and include these in an 
invention disclosure form (IDF) which would be submitted to Dublin City University as 
owners of any intellectual property generated during the programme.    
6.3 Final Conclusions and Lessons learned 
It is submitted that the process followed by the Dublin Bionnovate team was a success in 
view of the fact that a novel solution to an unmet clinical need was created and disclosed in 
the form of an invention disclosure.  It is acknowledged that the brainstorming, ideation and 
invention phases of the programme were more time consuming than originally envisaged yet 
the likelihood is that the additional time spent on these areas was necessary in order to 
produce a novel solution to an unmet clinical need.  While it may have been prudent to work 
concurrently in sub-groups to ensure that all targets of the programmes were met, it cannot be 
said how this would have affected the quality of the solutions produced. 
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While the output was most certainly a medical device which is capable of commercialisation, 
more work would be required with respect to topics such as reimbursement, regulatory 
matters and costs of product development as these had only been dealt with in a preliminary 
fashion.  However, the primary building blocks and requirements for successful 
commercialisation of the device were in place by the time the Fellowship drew to a close. 
Given that the unmet clinical needs had been appraised objectively in the initial phases, it had 
been ensured that the solution was addressing an unmet clinical need in a large market that 
was capable of having significant patient impact, reducing cost to the healthcare sector and, 
was capable of proof in a clinical trial relatively easily.  These facts, in addition to the fact 
that the actual solution proposed had the approval of key opinion leaders in the industry, 
sponsors of the programme and venture capitalists means that there is an increased likelihood 
of long-term success for the solution and a likelihood of sourcing commercialisation funding 
and seed capital required in the short-term future .  It can therefore be said that the 
BioInnovate programme provides a template for future innovations in the medical device 
sector. In addition to this, the eight Fellows who participated in the programme were 
provided with a unique understanding of the industry as well as the fundamental issues facing 
start-up medical device companies.  Therefore, in future years, BioInnovate Ireland can have 
a key role to play in the fulfilling the vision of the Innovation Taskforce. Furthermore, it is 
hoped the work done by the Fellows in terms of unearthing unmet clinical needs and 
researching these areas will be available for further research by future Fellows and industry 
partners in conjunction with the various higher education institutes.  
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